Injectable Contraceptives: Depo Provera

Injectable contraceptives are a popular form of birth control in the UK, with Depo Provera being the main option available. This contraceptive contains 150 mg of medroxyprogesterone acetate and is administered via intramuscular injection every 12 weeks. It can be given up to 14 weeks after the last dose without the need for extra precautions. The primary method of action is by inhibiting ovulation, while secondary effects include cervical mucous thickening and endometrial thinning.

However, there are some disadvantages to using Depo Provera. Once the injection is given, it cannot be reversed, and there may be a delayed return to fertility of up to 12 months. Adverse effects may include irregular bleeding and weight gain, and there is a potential increased risk of osteoporosis. It should only be used in adolescents if no other method of contraception is suitable.

It is important to note that there are contraindications to using Depo Provera, such as current breast cancer (UKMEC 4) or past breast cancer (UKMEC 3). While Noristerat is another injectable contraceptive licensed in the UK, it is rarely used in clinical practice and is given every 8 weeks. Overall, injectable contraceptives can be an effective form of birth control, but it is important to weigh the potential risks and benefits before deciding on this method.

If a mother is colonized with group B streptococcus, there is a slight risk of early onset sepsis in the newborn. If a newborn has only one minor risk factor for early onset sepsis, they should be kept in the hospital for at least 24 hours and monitored closely. If there are two or more minor risk factors or one red flag, the newborn should receive empirical antibiotic therapy with Benzylpenicillin and Gentamicin and undergo a full septic screen. Red flags include suspected or confirmed infection in another baby in the case of a multiple pregnancy, parenteral antibiotic treatment given to the woman for confirmed or suspected invasive bacterial infection during labor or in the 24-hour periods before and after birth (excluding intrapartum antibiotic prophylaxis), respiratory distress starting more than 4 hours after birth, seizures, need for mechanical ventilation in a term baby, and signs of shock.

Group B Streptococcus (GBS) is a common cause of severe infection in newborns. It is estimated that 20-40% of mothers carry GBS in their bowel flora, which can be passed on to their infants during labor and lead to serious infections. Prematurity, prolonged rupture of membranes, previous sibling GBS infection, and maternal pyrexia are all risk factors for GBS infection. The Royal College of Obstetricians and Gynaecologists (RCOG) has published guidelines on GBS management, which include not offering universal screening for GBS to all women and not offering screening based on maternal request. Women who have had GBS detected in a previous pregnancy should be offered intrapartum antibiotic prophylaxis (IAP) or testing in late pregnancy and antibiotics if still positive. IAP should also be offered to women with a previous baby with GBS disease, women in preterm labor, and women with a fever during labor. Benzylpenicillin is the preferred antibiotic for GBS prophylaxis.

It is likely that the patient is experiencing placental abruption, which is a medical emergency. The severity of the abruption and the risks to both the mother and the baby determine the management approach. This patient has risk factors such as chronic hypertension and smoking. Steroids should be administered to assist in fetal lung development if the fetus is alive, less than 36 weeks, and not in distress. The patient’s vital signs are stable, but the volume of vaginal bleeding may not accurately reflect the severity of the bleed. The fetal status is assessed using a cardiotocograph, which indicates whether the fetus is receiving adequate blood and nutrients from the placenta. Expectant management is not appropriate, and intervention is necessary to increase the chances of a positive outcome. Immediate caesarean section is only necessary if the fetus is in distress or if the mother is experiencing significant blood loss. Vaginal delivery is only appropriate if the fetus has died in utero, which is not the case here.

Placental Abruption: Causes, Management, and Complications

Placental abruption is a condition where the placenta separates from the uterine wall, leading to maternal haemorrhage. The severity of the condition depends on the extent of the separation and the gestational age of the fetus. Management of placental abruption is crucial to prevent maternal and fetal complications.

If the fetus is alive and less than 36 weeks, immediate caesarean delivery is recommended if there is fetal distress. If there is no fetal distress, close observation, administration of steroids, and no tocolysis are recommended. The decision to deliver depends on the gestational age of the fetus. If the fetus is alive and more than 36 weeks, immediate caesarean delivery is recommended if there is fetal distress. If there is no fetal distress, vaginal delivery is recommended. If the fetus is dead, vaginal delivery should be induced.

Placental abruption can lead to various maternal complications, including shock, disseminated intravascular coagulation (DIC), renal failure, and postpartum haemorrhage (PPH). Fetal complications include intrauterine growth restriction (IUGR), hypoxia, and death. The condition is associated with a high perinatal mortality rate and is responsible for 15% of perinatal deaths.

In conclusion, placental abruption is a serious condition that requires prompt management to prevent maternal and fetal complications. Close monitoring and timely intervention can improve the prognosis for both the mother and the baby.

The likely diagnosis for this patient is intrahepatic cholestasis of pregnancy, which commonly causes itching in the third trimester. This condition is characterized by elevated liver function tests (LFTs), particularly alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT), with a lesser increase in alanine transaminase (ALT). Patients may also experience jaundice, right upper quadrant pain, and steatorrhea. Treatment often involves ursodeoxycholic acid. Biliary colic is unlikely due to the absence of abdominal pain. Acute fatty liver of pregnancy is rare and presents with a hepatic picture on LFTs, along with nausea, vomiting, jaundice, and potential encephalopathy. HELLP syndrome is characterized by haemolytic anaemia and low platelets, which are not present in this case. Pre-eclampsia is also unlikely as the patient does not have hypertension or other related symptoms, although late pre-eclampsia may cause hepatic derangement on LFTs.

Liver Complications During Pregnancy

During pregnancy, there are several liver complications that may arise. One of the most common is intrahepatic cholestasis of pregnancy, which occurs in about 1% of pregnancies and is typically seen in the third trimester. Symptoms include intense itching, especially in the palms and soles, as well as elevated bilirubin levels. Treatment involves the use of ursodeoxycholic acid for relief and weekly liver function tests. Women with this condition are usually induced at 37 weeks to prevent stillbirth, although maternal morbidity is not typically increased.

Another rare complication is acute fatty liver of pregnancy, which may occur in the third trimester or immediately after delivery. Symptoms include abdominal pain, nausea and vomiting, headache, jaundice, and hypoglycemia. Severe cases may result in pre-eclampsia. ALT levels are typically elevated, and support care is the primary management until delivery can be performed once the patient is stabilized.

Finally, conditions such as Gilbert’s and Dubin-Johnson syndrome may be exacerbated during pregnancy. Additionally, HELLP syndrome, which stands for haemolysis, elevated liver enzymes, and low platelets, is a serious complication that can occur in the third trimester and requires immediate medical attention. Overall, it is important for pregnant women to be aware of these potential liver complications and to seek medical attention if any symptoms arise.

Intrahepatic cholestasis of pregnancy can lead to stillbirth, which is why doctors usually recommend inducing labor at 37-38 weeks of gestation.

Explanation:
The input statement is already clear and concise, so the output statement simply rephrases it in a slightly different way. It emphasizes the increased risk of stillbirth associated with intrahepatic cholestasis of pregnancy and highlights the recommended course of action for managing this risk.

Intrahepatic Cholestasis of Pregnancy: Symptoms and Management

Intrahepatic cholestasis of pregnancy, also known as obstetric cholestasis, is a condition that affects approximately 1% of pregnancies in the UK. It is characterized by intense itching, particularly on the palms, soles, and abdomen, and may also result in clinically detectable jaundice in around 20% of patients. Raised bilirubin levels are seen in over 90% of cases.

The management of intrahepatic cholestasis of pregnancy typically involves induction of labor at 37-38 weeks, although this practice may not be evidence-based. Ursodeoxycholic acid is also widely used, although the evidence base for its effectiveness is not clear. Additionally, vitamin K supplementation may be recommended.

It is important to note that the recurrence rate of intrahepatic cholestasis of pregnancy in subsequent pregnancies is high, ranging from 45-90%. Therefore, close monitoring and management are necessary for women who have experienced this condition in the past.

Ursodeoxycholic acid is the recommended initial medical treatment for intrahepatic cholestasis of pregnancy. The patient’s symptoms and abnormal liver function tests, along with her pregnancy status, suggest obstetric cholestasis. The Royal College of Obstetricians and Gynaecologists recommends ursodeoxycholic acid to alleviate pruritus and improve liver function in women with obstetric cholestasis. Cetirizine is not effective for pruritic symptoms during pregnancy, while cholestyramine is the preferred treatment for cholestatic pruritus but is not typically used for obstetric cholestasis. Dexamethasone is not the first-line therapy for obstetric cholestasis. Rifampicin may be used as an alternative treatment for pruritus, but caution should be exercised in patients with pre-existing liver disease due to potential hepatotoxicity, and it is not indicated for obstetric cholestasis.

Intrahepatic Cholestasis of Pregnancy: Symptoms and Management

Intrahepatic cholestasis of pregnancy, also known as obstetric cholestasis, is a condition that affects approximately 1% of pregnancies in the UK. It is characterized by intense itching, particularly on the palms, soles, and abdomen, and may also result in clinically detectable jaundice in around 20% of patients. Raised bilirubin levels are seen in over 90% of cases.

The management of intrahepatic cholestasis of pregnancy typically involves induction of labor at 37-38 weeks, although this practice may not be evidence-based. Ursodeoxycholic acid is also widely used, although the evidence base for its effectiveness is not clear. Additionally, vitamin K supplementation may be recommended.

It is important to note that the recurrence rate of intrahepatic cholestasis of pregnancy in subsequent pregnancies is high, ranging from 45-90%. Therefore, close monitoring and management are necessary for women who have experienced this condition in the past.

If the Bishop score is less than or equal to 6, the recommended method for inducing labor is through vaginal PGE2 or oral misoprostol. In this case, since the Bishop score was less than 5, labor is unlikely without induction. One option could be to repeat a membrane sweep, but the most appropriate course of action would be to use a vaginal prostaglandin gel.

Induction of labour is a process where labour is artificially started and is required in about 20% of pregnancies. It is indicated in cases of prolonged pregnancy, prelabour premature rupture of the membranes, maternal medical problems, diabetic mother over 38 weeks, pre-eclampsia, obstetric cholestasis, and intrauterine fetal death. The Bishop score is used to assess whether induction of labour is necessary and includes cervical position, consistency, effacement, dilation, and fetal station. A score of less than 5 indicates that labour is unlikely to start without induction, while a score of 8 or more indicates a high chance of spontaneous labour or response to interventions made to induce labour.

Possible methods of induction include membrane sweep, vaginal prostaglandin E2, oral prostaglandin E1, maternal oxytocin infusion, amniotomy, and cervical ripening balloon. The NICE guidelines recommend vaginal prostaglandins or oral misoprostol if the Bishop score is less than or equal to 6, while amniotomy and an intravenous oxytocin infusion are recommended if the score is greater than 6.

The main complication of induction of labour is uterine hyperstimulation, which refers to prolonged and frequent uterine contractions that can interrupt blood flow to the intervillous space and result in fetal hypoxemia and acidemia. Uterine rupture is a rare but serious complication. Management includes removing vaginal prostaglandins and stopping the oxytocin infusion if one has been started, and considering tocolysis.

A Hydatidiform mole, also known as a molar pregnancy, is a type of gestational trophoblastic disease that is precancerous. It occurs due to an imbalance in chromosomes during pregnancy, resulting in non-viable pregnancies. The main symptoms include painless vaginal bleeding in early pregnancy and a uterus that is larger than expected. The abnormal trophoblastic tissue can produce excessive amounts of human chorionic gonadotropin (hCG), leading to hyperemesis gravidarum and thyrotoxicosis. Ultrasound is a useful tool for diagnosis, with the mole appearing as a solid collection of echoes with numerous small anechoic spaces, resembling a bunch of grapes. It is important to note that a large uterus extending up to the umbilicus is indicative of a pregnancy that is large for dates, ruling out fibroids as a possible cause. Miscarriage and ectopic pregnancy are unlikely due to the absence of pain.

Gestational trophoblastic disorders refer to a range of conditions that originate from the placental trophoblast. These disorders include complete hydatidiform mole, partial hydatidiform mole, and choriocarcinoma. Complete hydatidiform mole is a benign tumor of trophoblastic material that occurs when an empty egg is fertilized by a single sperm that duplicates its own DNA, resulting in all 46 chromosomes being of paternal origin. Symptoms of this disorder include bleeding in the first or early second trimester, exaggerated pregnancy symptoms, a uterus that is large for dates, and very high levels of human chorionic gonadotropin (hCG) in the serum. Hypertension and hyperthyroidism may also be present. Urgent referral to a specialist center is necessary, and evacuation of the uterus is performed. Effective contraception is recommended to avoid pregnancy in the next 12 months, as around 2-3% of cases may develop choriocarcinoma.

Partial hydatidiform mole, on the other hand, occurs when a normal haploid egg is fertilized by two sperms or by one sperm with duplication of the paternal chromosomes. As a result, the DNA is both maternal and paternal in origin, and the fetus may have triploid chromosomes, such as 69 XXX or 69 XXY. Fetal parts may also be visible. It is important to note that hCG can mimic thyroid-stimulating hormone (TSH), which may lead to hyperthyroidism.

In summary, gestational trophoblastic disorders are a group of conditions that arise from the placental trophoblast. Complete hydatidiform mole and partial hydatidiform mole are two types of these disorders. While complete hydatidiform mole is a benign tumor of trophoblastic material that occurs when an empty egg is fertilized by a single sperm that duplicates its own DNA, partial hydatidiform mole occurs when a normal haploid egg is fertilized by two sperms or by one sperm with duplication of the paternal chromosomes. It is important to seek urgent medical attention and effective contraception to avoid pregnancy in the next 12 months.

Peripartum Complications: Sheehan’s Syndrome, Eclampsia, and Other Causes of Headache and Visual Disturbances

Peripartum complications can present with a variety of symptoms, including headache and visual disturbances. Sheehan’s syndrome is a condition that results from pituitary infarction due to haemorrhagic shock during labour and the peripartum period. It typically affects the anterior pituitary, leading to hormonal deficiencies that may present acutely or more indolently. Hormone replacement is the mainstay of treatment.

Eclampsia is another peripartum complication that can cause high blood pressure and seizures, sometimes leading to loss of consciousness. It requires urgent medical attention.

Other causes of headache and visual disturbances in the peripartum period include subarachnoid haemorrhage, which may present with sudden onset headache and visual disturbances, and extradural haemorrhage, which is typically found in trauma adjacent to fractures of the temporal bone. Occipital haemorrhagic infarction can also cause these symptoms, but a visual field defect is more suggestive of Sheehan’s syndrome.

It is important for healthcare providers to be aware of these potential complications and to promptly evaluate and manage them to ensure the best possible outcomes for both mother and baby.

Physiological Changes During Pregnancy

The human body undergoes significant physiological changes during pregnancy. The cardiovascular system experiences an increase in stroke volume by 30%, heart rate by 15%, and cardiac output by 40%. However, systolic blood pressure remains unchanged, while diastolic blood pressure decreases in the first and second trimesters, returning to non-pregnant levels by term. The enlarged uterus may interfere with venous return, leading to ankle edema, supine hypotension, and varicose veins.

The respiratory system sees an increase in pulmonary ventilation by 40%, with tidal volume increasing from 500 to 700 ml due to the effect of progesterone on the respiratory center. Oxygen requirements increase by only 20%, leading to over-breathing and a fall in pCO2, which can cause a sense of dyspnea accentuated by the elevation of the diaphragm. The basal metabolic rate increases by 15%, possibly due to increased thyroxine and adrenocortical hormones, making warm conditions uncomfortable for women.

The maternal blood volume increases by 30%, mostly in the second half of pregnancy. Red blood cells increase by 20%, but plasma increases by 50%, leading to a decrease in hemoglobin. There is a low-grade increase in coagulant activity, with a rise in fibrinogen and Factors VII, VIII, X. Fibrinolytic activity decreases, returning to normal after delivery, possibly due to placental suppression. This prepares the mother for placental delivery but increases the risk of thromboembolism. Platelet count falls, while white blood cell count and erythrocyte sedimentation rate rise.

The urinary system experiences an increase in blood flow by 30%, with glomerular filtration rate increasing by 30-60%. Salt and water reabsorption increase due to elevated sex steroid levels, leading to increased urinary protein losses. Trace glycosuria is common due to the increased GFR and reduction in tubular reabsorption of filtered glucose.

Calcium requirements increase during pregnancy, especially during the third trimester and lactation. Calcium is transported actively across the placenta, while serum levels of calcium and phosphate fall with a fall in protein. Ionized levels of calcium remain stable, and gut absorption of calcium increases substantially due to increased 1,25 dihydroxy vitamin D.

The liver experiences an increase in alkaline phosphatase by 50%,